Latest Advances in Lung Cancer Research

The Food and Drug Administration on Thursday approved Amgen’s therapy for patients with the most deadly form of lung cancer.

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

New NCCN guidelines help doctors treat lung cancer more effectively with early detection, personalized treatment plans, and comprehensive supportive care recommendations.

AstraZeneca’s Imfinzi shows promise in treating aggressive small cell lung cancer, potentially offering a new, more effective treatment option for this hard-to-treat disease.

The FDA granted accelerated approval for a new HER2-positive breast cancer treatment, offering hope to patients with advanced cancer after previous treatments have failed.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki, a new drug for treating HER2-positive unresectable or metastatic breast cancer in adults.

Cancer death rates in the U.S. have dropped 33% since 1991, saving 3.8 million lives, but disparities and challenges in certain cancers remain.

Cancer cases projected to rise 77% by 2050 due to aging populations, with low-income countries and lung cancer most affected, emphasizing prevention and global action.

Women’s lung cancer is often diagnosed late and treated less aggressively than men’s lung cancer, despite being the leading cause of cancer death among women.

Lung cancer rates are increasing among Asian American women, according to a new study published in the journal Cancer.

The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.